Chronic kidney disease (CKD) is a health epidemic that increases risk of death due to cardiovascular disease. By promoting heart failure, cardiac hypertrophy is an important pathology in CKD and affects up to 90% of patients by the time they reach dialysis. Fibroblast growth factor 23 (FGF23) is a bone-secreted hormone that regulates phosphate homeostasis. Serum FGF23 levels are constitutively elevated in CKD and continuously rise as patient's progress to renal failure. While this massive increase in FGF23 helps to maintain normal serum phosphate levels, prospective human studies demonstrated a dose-dependent association between higher FGF23 levels and greater risks of cardiovascular events and mortality. As a potential mechanism, we demonstrated that elevated FGF23 is strongly associated with cardiac hypertrophy in a large CKD cohort, and that FGF23 can induce hypertrophy in cultured cardiac myocytes and in a series of animal models with elevated serum FGF23. Our previous work suggests that FGF23 excess represents a novel, risk-multiplying mechanism of pathological cardiac hypertrophy in CKD. The purpose of this proposal is to identify the FGF23 receptor that is required for cardiac remodeling in CKD and the underlying signal mechanism in cardiac myocytes. Our preliminary data in heterologous cell cultures indicate that of the four FGF receptor isoforms (FGFR1-4), FGF23 can specifically activate FGFR4 which results in the activation of phospholipase C? (PLC?). Blockade of PLC?, calcineurin or FGFR4 inhibits FGF23-induced hypertrophic growth of cardiac myocytes in vitro. Different from wild type mice, elevating FGF23 in global FGFR4 knock-out mice by high phosphate diet does not because cardiac hypertrophy, and isolated cardiac myocytes from these mice are protected from FGF23-mediated hypertrophy.
In Aim 1 we will determine if FGFR4 activation is sufficient to induce cardiac hypertrophy. Our preliminary data indicate that an established knock-in mouse model with an FGFR4 gain-of- function mutation (FGFR4-G385R) has hypertrophy at 6-months of age, and we will analyze if these mice develop further cardiac injury including myocyte apoptosis and interstitial fibrosis leading to heart failure. Furthermore, we will analyze if cardiac remodeling in FGFR4-G385R mice is exacerbated in response to pressure overload or neuroendocrine stimulation.
In Aim 2 we want to study the mechanism of FGF23-FGFR4 mediated hypertrophy. We postulate that FGFR4 activation induces calcineurin/NFAT signaling in cardiac myocytes.
In Aim 3 we will analyze if FGFR4 is required for pathological cardiac remodeling in animals with prolonged FGF23 elevations. In a proof-of-concept experiment we want to determine if a highly specific FGFR4 blocking antibody attenuates hypertrophy in a rodent model of CKD. FGFR4 blockade might serve as a novel therapeutic strategy to prevent or treat heart failure in CKD, and potentially more generally in patients with other forms of cardiovascular disease.
Cardiac hypertrophy is an important mechanism of cardiovascular disease, which is the leading killer of the large number of patients with chronic kidney disease (CKD). In patients with CKD, circulating levels of fibroblast growth factor 23 (FGF23) are markedly elevated, which contributes mechanistically to cardiac hypertrophy. In this proposal, we will identify the cardiac FGF23 receptor (FGFR), and test the effects of a highly specific FGFR blocking antibody on the heart as a novel therapeutic approach. Our long-term goal is to translate this proof-of-concept approach into first-in-human trials in individuals with CKD.
| Faul, Christian (2018) FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int 94:7-11 |
| Krick, Stefanie; Grabner, Alexander; Baumlin, Nathalie et al. (2018) Fibroblast growth factor 23 and Klotho contribute to airway inflammation. Eur Respir J 52: |
| Kogan, Daniel; Grabner, Alexander; Yanucil, Christopher et al. (2018) STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. J Clin Invest 128:1867-1872 |
| Faul, Christian (2017) Cardiac actions of fibroblast growth factor 23. Bone 100:69-79 |
| Grabner, Alexander; Mazzaferro, Sandro; Cianciolo, Giuseppe et al. (2017) Fibroblast Growth Factor 23: Mineral Metabolism and Beyond. Contrib Nephrol 190:83-95 |
| Czaya, Brian; Singh, Saurav; Yanucil, Christopher et al. (2017) Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice. J Vis Exp : |
| Grabner, Alexander; Schramm, Karla; Silswal, Neerupma et al. (2017) FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep 7:1993 |
| Leifheit-Nestler, Maren; Grabner, Alexander; Hermann, Laura et al. (2017) Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Nephrol Dial Transplant 32:1493-1503 |
| Krick, Stefanie; Baumlin, Nathalie; Aller, Sheyla Paredes et al. (2017) Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia. Sci Rep 7:14388 |
| Munoz Mendoza, Jair; Isakova, Tamara; Cai, Xuan et al. (2017) Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 91:711-719 |
Showing the most recent 10 out of 17 publications
